Xeris Biopharma Holdings, Inc. (XERS)
| Market Cap | 1.66B +28.4% |
| Revenue (ttm) | 335.41M +36.3% |
| Net Income | -17.17M |
| EPS | -0.10 |
| Shares Out | 182.32M |
| PE Ratio | n/a |
| Forward PE | 53.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,546,958 |
| Open | 8.99 |
| Previous Close | 8.95 |
| Day's Range | 8.85 - 9.15 |
| 52-Week Range | 5.25 - 10.08 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 12.29 (+35.06%) |
| Est. Earnings | Nov 5, 2026 |
About XERS
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price target is $12.29, which is an increase of 35.06% from the latest price.
News
Xeris Biopharma Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Revenue growth is accelerating, driven by strong performance of three main products and high gross margins. XP-8121 targets a large unmet need in hypothyroidism, with a robust development and commercialization plan. RECORLEV continues to outperform, and further investments in infrastructure and potential business development are planned.
Xeris Biopharma price target raised to $16 from $12 at Leerink
Leerink raised the firm’s price target on Xeris Biopharma (XERS) to $16 from $12 and keeps an Outperform rating on the shares. The firm comes away with more conviction in…
Xeris Biopharma price target raised to $16 from $12 at Leerink
Leerink analyst Roanna Ruiz raised the firm’s price target on Xeris Biopharma (XERS) to $16 from $12 and keeps an Outperform rating on the shares.
Xeris Biopharma Holdings Transcript: Status update
XP-8121, a once-weekly subcutaneous levothyroxine, targets 3–5 million hypothyroid patients not controlled on oral therapy, with a comprehensive clinical program and strong IP protection. Launch is targeted for 2030, with peak sales potential of $1–3 billion and high physician interest.
Xeris Biopharma Holdings Slides: Status update
Xeris Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Xeris Biopharma Holdings Press release: Status update
Xeris Biopharma Holdings issued a press release on September 9, 2026, disclosing material business information to investors.
Xeris Biopharma hosts webinar on XP-8121 development program
Xeris Biopharma (XERS) will host an XP-8121 Program Overview at 10 a.m. ET detailing a comprehensive clinical development strategy, including Cornerstone, its Phase 3 registrational study design, as w...
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Details for XP-8121 Program Overview Webinar
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma price target raised to $12 from $9 at Barclays
Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $12 from $9 and keeps an Overweight rating on the shares after meeting with management. The firm left with…
Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026
Q2 delivered record revenue growth of 34% year-over-year, led by RECORLEV's 81% surge and strong rebounds from Gvoke and KEVEYIS. The company strengthened its IP portfolio, fully retired convertible notes, and raised 2026 revenue guidance to $385M-$390M.
Xeris Biopharma Holdings Earnings release: Q2 2026
Xeris Biopharma Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Xeris Biopharma Holdings Quarterly report: Q2 2026
Xeris Biopharma Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M
07:11 EDT Xeris Biopharma (XERS) tightens FY26 revnue view $385M-$390M, consensus $385.94M
Xeris Biopharma Reports Second Quarter 2026 Financial Results
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The...
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...
Xeris Biopharma appoints CEO John Shannon as chair of the board
Xeris Biopharma (XERS) announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as CEO, effective July 1. Shannon succeeds Marla…
Xeris Announces Updates to Its Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient liv...
Xeris Biopharma announces private exchange of convertible notes
Xeris Biopharma (XERS) entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028. Pursuant to the exchange agreements, Xeris h...
Xeris Biopharma Announces Private Exchange of Convertible Notes
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026
Revenue grew 43% in Q1, driven by RECORLEV, with expanded commercial reach and strong new patient growth. XP-8121 is advancing to phase III, targeting a 2030 launch. Patent protection for RECORLEV extends to 2040, and financial strength supports ongoing investment.
Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 43% net product revenue growth, led by RECORLEV's 95% surge and strong KEVEYIS performance, while GVOKE was flat due to Medicare headwinds. Full-year revenue guidance was raised, and commercial expansion is expected to drive further growth.